Lilly breakthrough offers real hope for people with early Alzheimer's

While targeted protein-busting antibodies are  revolutionizing the treatment of Alzheimer’s disease, a damaging side effect - amyloid-related imaging abnormalities (ARIA) - has emerged as a differentiator among the  growing number of options.

One such biologic, donanemab,  offers hope that a limited duration treatment strategy - stopping dosing once the aberrant protein plaques have been removed - could benefit patients while avoiding such outcomes.

Developer Eli Lilly (NYSE: LLY) has now presented striking details from the Phase III program for the antibody, showing increasing treatment benefit over the course of the trial, even months after infusions were stopped.